Abstract
Myc family genes are often deregulated in embryonal tumors of childhood including medulloblastoma and neuroblastoma and are frequently associated with aggressive, poorly differentiated tumors. The Myc protein is a transcription factor that regulates a variety of cellular processes including cell growth and proliferation, cell cycle progression, differentiation, apoptosis, and cell motility. Potential strategies that either inhibit the proliferation-promoting effect of Myc and/or activate its pro-apoptotic function are presently being explored. In this review, we will give an overview of Myc activation in embryonal tumors and discuss current strategies aimed at targeting Myc for cancer treatment.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Antineoplastic Agents / pharmacology*
-
Central Nervous System Neoplasms / drug therapy*
-
Central Nervous System Neoplasms / genetics*
-
Central Nervous System Neoplasms / metabolism
-
Child
-
Humans
-
Medulloblastoma / drug therapy
-
Medulloblastoma / genetics
-
Medulloblastoma / metabolism
-
Mice
-
Mice, Transgenic
-
Neoplasms, Germ Cell and Embryonal / drug therapy
-
Neoplasms, Germ Cell and Embryonal / genetics
-
Neoplasms, Germ Cell and Embryonal / metabolism
-
Neuroblastoma / drug therapy
-
Neuroblastoma / genetics
-
Neuroblastoma / metabolism
-
Peripheral Nervous System Neoplasms / drug therapy*
-
Peripheral Nervous System Neoplasms / genetics*
-
Peripheral Nervous System Neoplasms / metabolism
-
Proto-Oncogene Proteins c-myc / drug effects*
-
Proto-Oncogene Proteins c-myc / genetics
-
Proto-Oncogene Proteins c-myc / metabolism
-
Rhabdoid Tumor / drug therapy
-
Rhabdoid Tumor / genetics
-
Rhabdoid Tumor / metabolism
Substances
-
Antineoplastic Agents
-
Proto-Oncogene Proteins c-myc